| Quarter (USD) | Sep 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|
| Revenue | ||||
| Cost of revenue | ||||
| Operating income | ||||
| Operating margin | ||||
| Net income | ||||
| Net profit margin | ||||
| Cash on hand | ||||
| Change in cash | ||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 46.06 mm | 46.06 mm | 46.06 mm | 46.06 mm | 46.06 mm | 46.06 mm |
| Cash burn (monthly) | 2.69 mm | 2.14 mm | 4.14 mm | 6.00 mm | 293.33 k | 5.08 mm |
| Cash used (since last report) | 7.53 mm | 5.99 mm | 11.58 mm | 16.81 mm | 821.29 k | 14.23 mm |
| Cash remaining | 38.53 mm | 40.07 mm | 34.48 mm | 29.25 mm | 45.24 mm | 31.83 mm |
| Runway (months of cash) | 14.3 | 18.7 | 8.3 | 4.9 | 154.2 | 6.3 |
| 13F holders | Current |
|---|---|
| Total holders | 74 |
| Opened positions | 37 |
| Closed positions | 15 |
| Increased positions | 12 |
| Reduced positions | 15 |
| 13F shares | Current |
|---|---|
| Total value | 46.99 bn |
| Total shares | 41.72 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Atlas Venture Life Science Advisors | 5.02 mm | $8.28 bn |
| BVF | 4.77 mm | $7.87 bn |
| Blue Owl Capital | 4.09 mm | $6.75 bn |
| Orbimed Advisors | 3.54 mm | $5.84 bn |
| GILD Gilead Sciences | 2.93 mm | $12.28 mm |
| Atlas Venture Fund X | 2.90 mm | $74.28 mm |
| Biotechnology Value Fund L P | 2.50 mm | $0.00 |
| Omega Fund Management | 2.25 mm | $3.71 bn |
| Omega Fund VI | 2.25 mm | $0.00 |
| BMY Bristol-Myers Squibb | 2.13 mm | $0.00 |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 7 Jun 24 | Formela Jean Francois | Stock Option Common Stock | Grant | Acquire A | No | No | 1.75 | 17,520 | 30.66 k | 17,520 |
| 7 Jun 24 | Owen Hughes | Stock Option Common Stock | Grant | Acquire A | No | No | 1.75 | 17,520 | 30.66 k | 17,520 |
| 7 Jun 24 | Dukes Iain D. | Stock Option Common Stock | Grant | Acquire A | No | No | 1.75 | 17,520 | 30.66 k | 17,520 |
| 7 Jun 24 | Maria Koehler | Stock Option Common Stock | Grant | Acquire A | No | No | 1.75 | 17,520 | 30.66 k | 17,520 |
| 7 Jun 24 | Stampacchia Otello | Stock Option Common Stock | Grant | Acquire A | No | No | 1.75 | 17,520 | 30.66 k | 17,520 |
